Drug · CHEMBL650
METHYLPREDNISOLONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. METHYLPREDNISOLONE. Drugs and targets, record CHEMBL650. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL650
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 6-methyl-prednisolone, 6-methylprednisolone, J3.872E, Metilprednisolona, NSC-19987, U-67,590A
- ChEMBL
- Open Targets' highest stage
- Approval, for 17 of its 309 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | Glucocorticoid receptor agonist | AGONIST | https://conductscience.org/library/genes/2908 |
Source ChEMBL
Diseases309
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 24 | 24 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| COVID-19 | Phase 3 | ClinicalTrials.gov | 21 | 21 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| multiple sclerosis symptom measurement | Approval | DailyMed | 45 | 19 | https://conductscience.org/library/drugs?q=EFO_0803536 |
| asthma | Approval | DailyMed | 40 | 19 | https://conductscience.org/library/drugs?q=MONDO_0004979 |
| acute graft versus host disease | Phase 3 | ClinicalTrials.gov | 18 | 18 | https://conductscience.org/library/drugs?q=MONDO_0020546 |
| graft versus host disease | Phase 3 | ClinicalTrials.gov | 18 | 18 | https://conductscience.org/library/drugs?q=MONDO_0013730 |
| acute respiratory distress syndrome | Phase 3 | ClinicalTrials.gov | 17 | 17 | https://conductscience.org/library/drugs?q=MONDO_0006502 |
| osteoarthritis | Approval | DailyMed | 38 | 16 | https://conductscience.org/library/drugs?q=MONDO_0005178 |
| hematopoietic and lymphoid cell neoplasm | Phase 2/3 | ClinicalTrials.gov | 16 | 16 | https://conductscience.org/library/drugs?q=MONDO_0044881 |
| Graves ophthalmopathy | Phase 3 | ClinicalTrials.gov | 14 | 14 | https://conductscience.org/library/drugs?q=EFO_1001466 |
1 to 10 of 309Source Open Targets
See all 309 diseasesTrials677
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 26 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 440 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03229538 | STeroids to REduce Systemic Inflammation After Infant Heart Surgery | Phase 3 | 1,263 | 2023-05-10 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | Phase 3 | 600 | 2023-05-31 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT01283009 | Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e) | Phase 3 | 584 | 2020-10-08 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT03640949 | Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest | Phase 2/3 | 501 | 2022-01-11 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT01430403 | Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations | Phase 4 | 478 | 2015-09-16 | corticosteroids | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00458848 | Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia | Phase 2 | 470 | 2019-02-15 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT03139604 | GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease | Phase 3 | 439 | 2020-05-15 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT01238536 | Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial) | Phase 4 | 400 | 2017-12-13 | glucocorticoids | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01382940 | A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis | Phase 4 | 351 | 2014-02-19 | methylprednisolone | Its name | ClinicalTrials.gov |
| NCT03649061 | COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA | Phase 4 | 276 | 2025-06-19 | glucocorticoid | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
1 to 10 of 677
See all 677 trialsComparisons in its trials149
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Prolonged Mechanical Ventilation (Greater Than 7 Days) | 41 of 599 | 51 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Post-operative Low Cardiac Output Syndrome | 31 of 599 | 37 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Mortality, Including In-hospital Mortality or Mortality After Hospital Discharge But Within 30 Days of the Last Dose of Study Drug | 12 of 599 | 17 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Death or Major Complication as Defined by an Outcome in One of the 7 Highest Global Ranking Categories | 103 of 599 | 122 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Any Other Post-operative Complications From the Start of Study Drug Administration Until Hospital Discharge. | 237 of 599 | 264 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With a Post-operative Length of Stay Greater Than 90 Days | 18 of 599 | 29 of 601 | 1,200 | NCT03229538 | Trial comparisons |
Methylprednisolone Arm vs Placebo Arm: Number of Participants With Occurrence of Any One or More of the Following STS-CHSD-defined Major Post-operative Infectious Complications: Postprocedural Infective Endocarditis, Pneumonia, Sepsis, Deep Wound Infection, Mediastinitis. | 31 of 599 | 24 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: deaths from any cause | 12 of 599 | 17 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: serious adverse events | 2 of 599 | 0 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): deaths from any cause | 4 of 289 | 2 of 298 | 587 | NCT02166463 | Trial comparisons |
1 to 10 of 149
See all 149 comparisons in its trialsPapers from its trials365
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Coding | 3 | 1 | ConductCognition |
| Trail Making Test A | 2 | 0 | ConductCognition |
| Trail Making Test B | 2 | 0 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Paced Visual Serial Addition Test | 1 | 0 | ConductCognition |
| Task Switching Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL650
GET https://conductscience.org/api/drugs/v1/CHEMBL650/diseases?page=2